BMS loses UK appeal over blood-thinning drug

09-05-2023

Liz Hockley

BMS loses UK appeal over blood-thinning drug

nitpicker / Shutterstock.com

Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.


patent, plausibility, appeal, Bristol Myers Squibb, Teva, Sandoz, apixaban, invalid, compound

LSIPR